Matthias Ocker

14PUBLICATIONS
24CO-AUTHORS
Cancer diagnosisCancer geneticsMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Mar 27, 2026
Translating Fibrosis to Malignancy: Biomarkers and Therapeutic Opportunities in Liver Fibrosis and Hepatocellular Carcinoma.

Daniel Neureiter, Tobias Kiesslich, Matthias Ocker

|Jan 22, 2025
The importance of preclinical models for cholangiocarcinoma drug discovery.

Felix J Krendl, Florian Primavesi, Rupert Oberhuber

|Aug 23, 2024
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.

Ulrike Rauh, Guo Wei, Michael Serrano-Wu

|Apr 11, 2024
The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells.

Dino Bekric, Tobias Kiesslich, Matthias Ocker

|Feb 14, 2024
Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials.

Dominik Kiem, Matthias Ocker, Richard Greil

|Feb 11, 2023
Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model.

Mari I Suominen, Matias Knuuttila, Christoph A Schatz

Pageof 3

Frequent Collaborators

9 joint publications

Daniel Neureiter

3 joint publications

Sebastian Stintzing

2 joint publications

Tobias Kiesslich

2 joint publications

Markus Ritter